CCNB1, CDK1, and RRM2 have been reported to be enriched in the p53 signaling pathway and are believed to act as potential biomarkers and therapeutic targets for hepatitis B virus-associated hepatocellular carcinoma [52]. This evidence concerns the gene RRM2 and hepatocellular carcinoma.